Allan Oliveira Santos

Allan Oliveira Santos

Auto-generated profile, based on publicly available information

Allan Oliveira Santos

Universidade Estadual de Campinas, Brazil

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
DADalton A. Anjos
Dalton A. Anjos
EEElba Etchebehere
Elba Etchebehere
CRCelso D. Ramos
Celso D. Ramos
ASAllan O. Santos
Allan O. Santos
CACésar Albertotti
César Albertotti
ECEdwaldo E. Camargo
Edwaldo E. Camargo
PET with 18F-FDG has been considered of limited value for detection of bladder cancer because of the urinary excretion of the tracer. The purpose of this study was to investigate the role of PET/CT in the detection and restaging of bladder cancer using furosemide and oral hydration to remove the excreted 18F-FDG from the bladder. Methods: Seventeen patients with bladder cancer (11 without cystectomy, 6 with total cystectomy and urinary diversion) underwent 18F-FDG PET/CT from head to the upper thighs 60 min after the intravenous injection of 370 MBq of 18F-FDG. Additional pelvic images were acquired 1 h after the intravenous injection of furosemide and oral hydration. PET/CT findings were confirmed by MRI, cystoscopy, or biopsy. Results: PET/CT was able to detect bladder lesions in 6 of 11 patients who had not undergone cystectomy. These images changed the PET/CT final reading in 7 patients: Recurrent bladder lesions were detected in 6 patients, pelvic lymph node metastases in 2 patients, and prostate metastasis in 1. This technique overcame the difficulties posed by the urinary excretion of 18F-FDG. Hypermetabolic lesions could be easily detected by PET and precisely localized in the bladder wall, pelvic lymph nodes, or prostate by CT. Seven of 17 patients (41%) were upstaged only after delayed pelvic images. Conclusion: Detection of locally recurrent or residual bladder tumors can be dramatically improved using 18F-FDG PET/CT with delayed images after a diuretic and oral hydration.

4 August 2012 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
DBDaniel C. Bortot
Daniel C. Bortot
BABárbara J. Amorim
Bárbara J. Amorim
GOGlaucia C. Oki
Glaucia C. Oki
SGSérgio B. Gapski
Sérgio B. Gapski
ASAllan O. Santos
Allan O. Santos
CRCelso Dario Ramos
Celso Dario Ramos

1 August 2001 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
EEElba Etchebehere
Elba Etchebehere
FCFernando Cendes
Fernando Cendes
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
JPJuliana A. Pereira
Juliana A. Pereira
MLMariana C. L. Lima
Mariana C. L. Lima
ECEdwaldo E. Camargo
Edwaldo E. Camargo
MACHADO-JOSEPH disease (MJD) is one of the most frequently encountered spinocerebellar ataxias. Machado-Joseph disease was first described in 1972 by Nakano et al1 in a Portuguese-American family, which descended from Guilherme Machado, and emigrated from the Azores to Massachusetts. Since then, the disease has been described in other countries.2-7

1 November 2005 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
CRCelso D. Ramos
Celso D. Ramos
ASAllan O. Santos
Allan O. Santos
MLMarcelo M.O. Lima
Marcelo M.O. Lima
APAnita D. Panzan
Anita D. Panzan
ECEdwaldo E. Camargo
Edwaldo E. Camargo
Several factors may interfere with the success rate of radioiodine therapy (RIT) in Graves' disease. Our aim was to evaluate, retrospectively, some of these factors in the outcome of RIT. Patient gender, age at diagnosis, ophthalmopathy, disease duration, thyroid size, drug used as clinical treatment, thionamide withdrawal period during RIT preparation, FT4, TSH and [99mTc]pertechnetate thyroid uptake prior to RIT were studied as potential interference factors for RIT success. Eighty-two Graves' disease patients were submitted to RIT after thionamide treatment failure. Prior to RIT, 67 patients were receiving methimazole and 15 propylthiouracil. Thirty-three patients received thionamides during RIT; in 49 patients the medication was withdrawn for 2–30 days. [99mTc]pertechnetate thyroid uptake was determined before RIT. Fixed doses of 370 MBq of [131I]iodide were administered to all patients. Eleven patients became euthyroid; 40 became hypothyroid and 31 remained hyperthyroid. There was no association between outcome and age at diagnosis, gender, ophthalmopathy, pre-RIT FT4, TSH, antithyroid antibodies or thyrostatic drug. Multiple logistic regression showed higher probability of treatment success in patients with thyroid mass <53 g (odds ratio (OR)=8.9), with pre-RIT thyroid uptake <12.5% (OR=4.1) and in patients who withdrew thionamide before RIT (OR=4.9). Fixed doses of 370 MBq of radioiodine seem to be practical and effective for treating Graves' disease patients with [99mTc]pertechnetate uptake <12.5% and thyroid mass <53 g. This treatment is clearly not recommended for patients with large goitre. In contrast to what could be expected, patients with a high pre-RIT thyroid uptake presented a higher rate of RIT failure.

1 January 2014 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
NSNailú Angélica Sinicato
Nailú Angélica Sinicato
MPMariana Postal
Mariana Postal
FPFernando Augusto Peres
Fernando Augusto Peres
KPKarina de Oliveira Peliçari
Karina de Oliveira Peliçari
RMRoberto Marini
Roberto Marini
SASimone Appenzeller
Simone Appenzeller
Background. In systemic lupus erythematosus (SLE), atherosclerosis is attributed to traditional and lupus related risk factors, including metabolic syndrome (MetS), obesity, and inflammation.Objective. To evaluate the association between obesity, measures of body fat content, serum tumor necrosis factor alpha (TNF-α), and interleukin (IL)-6 and -10 levels in childhood-onset SLE (cSLE).Methods. We screened consecutive cSLE patients followed up in the Pediatric Rheumatology Outpatient Clinic of the State University of Campinas. cSLE patients were assessed for disease and damage. Obesity was definite as body mass index (BMI) ≥30 kg/m2. Serum TNF-α, IL-6, and IL-10 levels were measured by ELISA. Dual-energy X-ray absorptiometry was used to determine total fat mass, lean mass, and percent of body fat.Results. We included 52 cSLE patients and 52 controls. cSLE patients had higher serum TNF-α (P=0.004), IL-6(P=0.002), and IL-10(P<0.001)levels compared to controls. We observed higher serum TNF-α (P=0.036)levels in cSLE patients with obesity. An association between serum TNF-αlevels and body fat percent(P=0.046)and total fat mass on trunk region(P=0.035)was observed.Conclusion. Serum TNF-αlevels were associated with obesity and body fat content in cSLE. Our finding suggests that obesity may contribute to the increase of serum TNF-αlevels in cSLE.

1 April 2006 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
DADalton A. Anjos
Dalton A. Anjos
EEElba Etchebehere
Elba Etchebehere
ASAllan O. Santos
Allan O. Santos
MLMariana C.L. Lima
Mariana C.L. Lima
CRCelso D. Ramos
Celso D. Ramos
ECEdwaldo E. Camargo
Edwaldo E. Camargo
The assessment of the functional status of the salivary glands has been used in the scintigraphic evaluation of xerostomia. Several quantitative methods derived from standard dynamic scintigraphy have been suggested. However, the indices proposed are quite variable and unlikely to be useful in clinical practice. The objectives of this study were to obtain reference values of major salivary glands uptake and excretion fraction in healthy subjects and to obtain normal ratios of 99mTc-pertechnetate uptake by the major salivary glands in comparison to the thyroid gland uptake. The standardization of these values has the purpose of making this evaluation faster and more objective. Fifty volunteers without clinical evidence of xerostomia or thyroid disease underwent static salivary glands scintigraphy with 99mTc-pertechnetate. Static images were obtained at 20 minutes and then at 3 minutes after oral stimulation with lemon juice. Percent uptake, excretion fraction and salivary gland to thyroid ratio rates were calculated for the parotid and the submandibular glands. The mean of the uptake values at 20 minutes for the right and left parotid glands were respectively 0.31% and 0.26%, and for the submandibular glands 0.15%. The excretion fraction of the tracer after the lemon juice stimulation was 70% for the parotids glands, 50% for the right and 49% for the left submandibular glands. The mean±SD salivary gland to thyroid count ratio was 0.79±0.45 for the right parotid, 0.78±0.5 for the left parotid, 0.67±0.33 and 0.66±0.34 for the right and left submandibular glands, respectively. Salivary glands scintigraphy with uptake and excretion fraction calculation is an easy to perform, non-invasive and objective method to investigate salivary glands function. These findings help the nuclear physician to interpret salivary gland scintigraphy more objectively, even in patients with thyroid gland dysfunction in whom 99mTc-pertechnetate thyroid uptake may be abnormal